Evidence map›Paper›PMID 34204302›Full record

ReviewJournal of personalized medicine2021

In Situ Delivery and Production System (

Shun'ichiro Taniguchi

Open access · goldAbstract readReview
In one paragraph

Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. EngineeredCancers · 2025
    Review
  3. Article
  4. Article
  5. Recent Development of ProbioticFrontiers in bioengineering and biotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Shun'ichiro TaniguchiDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto City 390-8621, Japan.
Shinshu University · JP

Funding

Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science 18K06781, 15K08022
6 · The paper itself

Abstract

To selectively and continuously produce anti-cancer molecules specifically in malignant tumors, we have established an in situ delivery and production system (

Indexed as

anaerobic bacteriabacterial therapyBifidobacteriumcancer therapyDDSEPRhypoxiaiDPSmicroenvironmentsolid cancer

Identifiers

PMID34204302
PMCPMC8233750
OpenAlexW3172649576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.